Sarepta Therapeutics Inc. (NASDAQ:SRPT)’s share price rose 5% during mid-day trading on Thursday . The company traded as high as $25.46 and last traded at $25.24, with a volume of 1,036,806 shares. The stock had previously closed at $24.03.

SRPT has been the topic of a number of research reports. Needham & Company LLC reiterated a “buy” rating and set a $20.00 target price (down from $53.00) on shares of Sarepta Therapeutics in a research report on Sunday, April 24th. Jefferies Group reiterated a “sell” rating and set a $7.00 target price on shares of Sarepta Therapeutics in a research report on Friday, May 6th. Leerink Swann reiterated an “underperform” rating and set a $5.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, August 4th. Vetr lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating and set a $17.28 target price on the stock. in a research report on Monday, May 23rd. Finally, Robert W. Baird restated an “outperform” rating and issued a $23.00 price objective on shares of Sarepta Therapeutics in a report on Monday, July 18th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $25.28.

The firm’s market capitalization is $1.14 billion. The firm’s 50-day moving average price is $22.28 and its 200-day moving average price is $18.13.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same period in the previous year, the company earned ($0.87) EPS. On average, analysts forecast that Sarepta Therapeutics Inc. will post ($5.15) EPS for the current year.

Several hedge funds and institutional investors have recently modified their holdings of SRPT. Jennison Associates LLC increased its position in shares of Sarepta Therapeutics by 463.6% in the fourth quarter. Jennison Associates LLC now owns 838,629 shares of the company’s stock worth $32,354,000 after buying an additional 689,831 shares during the period. Mutual of America Capital Management LLC increased its position in shares of Sarepta Therapeutics by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 60,108 shares of the company’s stock worth $2,319,000 after buying an additional 358 shares during the period. New York State Common Retirement Fund increased its position in shares of Sarepta Therapeutics by 13.5% in the fourth quarter. New York State Common Retirement Fund now owns 44,700 shares of the company’s stock worth $1,725,000 after buying an additional 5,300 shares during the period. Rhumbline Advisers increased its position in shares of Sarepta Therapeutics by 16.1% in the fourth quarter. Rhumbline Advisers now owns 47,728 shares of the company’s stock worth $1,841,000 after buying an additional 6,615 shares during the period. Finally, Swiss National Bank increased its position in shares of Sarepta Therapeutics by 5.8% in the fourth quarter. Swiss National Bank now owns 61,700 shares of the company’s stock worth $2,380,000 after buying an additional 3,400 shares during the period.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.